With in-person events back again, Creative Biolabs is excited to greet you at the upcoming international conferences. Meet our team at 2022 BIO International Convention in June (booth #1754) and at the 13th Annual World ADC San Diego in September (booth number to be updated) for expert consultation on your drug discovery. Shoot an email to arrange an in-person meeting!
Cooperation SeekingCreative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced rituximab. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
Similar to the parental antibody Loncastuximab, ADCC-Enhanced Anti-Human CD19 (Loncastuximab) Antibody targets to the antigen CD19, achieving ADCC-enhanced antibody by reducing fucosylation of the Fc region of parental antibody, leading to an increased binding affinity for the FcyR receptor on immune effector cells.
All products and services are for Research Use Only. Do Not use in humans.
Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.